In an experimentally induced PCOS rat model, supplementation with sodium acetate—a SCFA and histone deacetylase (HDAC) inhibitor—ameliorated hyperinsulinemia, dyslipidemia, and ovarian oxidative stress while restoring 17β-estradiol levels, sex hormone-binding globulin (SHBG) expression, and ovarian histoarchitecture. Here, SHBG is linked to metabolic syndrome.